Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce pill burden of COVID-19 treatment
August 2020: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of...
Read more






























